Switch theme
Sign up to access all valuation multiples
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
2015
55
LTM Revenue n/a
LTM EBITDA n/a
-$84.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kezar Life Sciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Kezar Life Sciences achieved revenue of n/a and an EBITDA of -$81.1M.
Kezar Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kezar Life Sciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $7.0M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$99.3M | -$81.1M | XXX | XXX | XXX |
| EBITDA Margin | -1418% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$68.2M | -$102M | XXX | XXX | XXX |
| Net Margin | -975% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Kezar Life Sciences's stock price is $4.
Kezar Life Sciences has current market cap of $31.6M, and EV of -$84.5M.
See Kezar Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$84.5M | $31.6M | XXX | XXX | XXX | XXX | $-10.81 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Kezar Life Sciences has market cap of $31.6M and EV of -$84.5M.
Kezar Life Sciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Kezar Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Kezar Life Sciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$84.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 1.0x | XXX | XXX | XXX |
| P/E | -0.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKezar Life Sciences's NTM/LTM revenue growth is n/a
Kezar Life Sciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.
Over next 12 months, Kezar Life Sciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Kezar Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Kezar Life Sciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kezar Life Sciences acquired XXX companies to date.
Last acquisition by Kezar Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Kezar Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Kezar Life Sciences founded? | Kezar Life Sciences was founded in 2015. |
| Where is Kezar Life Sciences headquartered? | Kezar Life Sciences is headquartered in United States of America. |
| How many employees does Kezar Life Sciences have? | As of today, Kezar Life Sciences has 55 employees. |
| Who is the CEO of Kezar Life Sciences? | Kezar Life Sciences's CEO is Dr. Christopher Kirk, PhD. |
| Is Kezar Life Sciences publicy listed? | Yes, Kezar Life Sciences is a public company listed on NAS. |
| What is the stock symbol of Kezar Life Sciences? | Kezar Life Sciences trades under KZR ticker. |
| When did Kezar Life Sciences go public? | Kezar Life Sciences went public in 2018. |
| Who are competitors of Kezar Life Sciences? | Similar companies to Kezar Life Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kezar Life Sciences? | Kezar Life Sciences's current market cap is $31.6M |
| Is Kezar Life Sciences profitable? | Yes, Kezar Life Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
